328 related articles for article (PubMed ID: 36082692)
21. Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.
Chen X; Shi X; Wang X; Liu J
Cancer Cell Microenviron; 2014 Nov; 1(6):. PubMed ID: 25995993
[TBL] [Abstract][Full Text] [Related]
22. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
23. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
24. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.
Lei H; Xu HZ; Shan HZ; Liu M; Lu Y; Fang ZX; Jin J; Jing B; Xiao XH; Gao SM; Gao FH; Xia L; Yang L; Liu LG; Wang WW; Liu CX; Tong Y; Wu YZ; Zheng JK; Chen GQ; Zhou L; Wu YL
Nat Commun; 2021 Jan; 12(1):51. PubMed ID: 33397955
[TBL] [Abstract][Full Text] [Related]
25. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
Lai HR; Wu QM; Yang YZ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
[No Abstract] [Full Text] [Related]
26. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
27. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
[TBL] [Abstract][Full Text] [Related]
28. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
[TBL] [Abstract][Full Text] [Related]
29. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y
Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903
[TBL] [Abstract][Full Text] [Related]
30. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q
Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066
[TBL] [Abstract][Full Text] [Related]
31. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.
Elsir Khair H; Ahmed Mohamed B; Yousef Nour B; Ali Waggiallah H
Pak J Biol Sci; 2022 Jan; 25(2):175-181. PubMed ID: 35234007
[TBL] [Abstract][Full Text] [Related]
33. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
34. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 3-((3-amino-
El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410
[TBL] [Abstract][Full Text] [Related]
38. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
39. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
40. ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Wang Z; Liu Z; Wu X; Chu S; Wang J; Yuan H; Roth M; Yuan YC; Bhatia R; Chen W
PLoS Genet; 2014 Jun; 10(6):e1004414. PubMed ID: 24967705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]